1. Home
  2. WING vs CELC Comparison

WING vs CELC Comparison

Compare WING & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wingstop Inc.

WING

Wingstop Inc.

N/A

Current Price

$153.21

Market Cap

4.1B

ML Signal

N/A

Logo Celcuity Inc.

CELC

Celcuity Inc.

N/A

Current Price

$56.47

Market Cap

4.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WING
CELC
Founded
1994
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Medical Specialities
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.2B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
WING
CELC
Price
$153.21
$56.47
Analyst Decision
Buy
Strong Buy
Analyst Count
27
13
Target Price
★ $184.92
$150.85
AVG Volume (30 Days)
★ 1.4M
935.0K
Earning Date
10-28-2026
11-05-2026
Dividend Yield
★ 0.85%
N/A
EPS Growth
★ 67.84
N/A
EPS
★ 3.30
N/A
Revenue
★ $696,853,000.00
N/A
Revenue This Year
$7.16
N/A
Revenue Next Year
$14.63
$1,921.71
P/E Ratio
$44.68
★ N/A
Revenue Growth
★ 11.35
N/A
52 Week Low
$95.82
$53.54
52 Week High
$302.80
$151.02

Technical Indicators

Market Signals
Indicator
WING
CELC
Relative Strength Index (RSI) 54.14 34.05
Support Level $139.01 $53.54
Resistance Level $177.19 $72.76
Average True Range (ATR) 9.46 4.26
MACD -2.44 -0.82
Stochastic Oscillator 25.28 10.75

Price Performance

Historical Comparison
WING
CELC

About WING Wingstop Inc.

Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across over 10 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 stores, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Share on Social Networks: